KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Repurchased
Ratios

Emergent BioSolutions (EBS) Long-Term Debt Issuances (2019 - 2024)

Historic Long-Term Debt Issuances for Emergent BioSolutions (EBS) over the last 8 years, with Q3 2024 value amounting to $154.0 million.

  • Emergent BioSolutions' Long-Term Debt Issuances changed N/A to $154.0 million in Q3 2024 from the same period last year, while for Jun 2025 it was $154.0 million, marking a year-over-year increase of 8117.65%. This contributed to the annual value of $219.0 million for FY2024, which is 99500.0% up from last year.
  • Latest data reveals that Emergent BioSolutions reported Long-Term Debt Issuances of $154.0 million as of Q3 2024.
  • Emergent BioSolutions' 5-year Long-Term Debt Issuances high stood at $360.0 million for Q4 2022, and its period low was $15.0 million during Q2 2024.
  • Its 3-year average for Long-Term Debt Issuances is $119.8 million, with a median of $50.0 million in 2024.
  • Data for Emergent BioSolutions' Long-Term Debt Issuances shows a peak YoY increase of 9444.44% (in 2023) and a maximum YoY decrease of 9444.44% (in 2023) over the last 5 years.
  • Quarter analysis of 3 years shows Emergent BioSolutions' Long-Term Debt Issuances stood at $360.0 million in 2022, then plummeted by 94.44% to $20.0 million in 2023, then soared by 670.0% to $154.0 million in 2024.
  • Its Long-Term Debt Issuances was $154.0 million in Q3 2024, compared to $15.0 million in Q2 2024 and $50.0 million in Q1 2024.